Emerging Therapies Aim to Revolutionize Spinal Cord Injury Treatment

New pipeline candidates target neuronal regeneration, pain relief, and more

Apr. 2, 2026 at 5:37pm

Got story updates? Submit your updates here. ›

The spinal cord injury treatment landscape is undergoing a significant transformation, with several innovative therapies in development that could reshape the future of SCI management. Emerging candidates like KP-100IT, Neuro-Cells, MT-3921, Elezanumab, NFX88, and NVG-291 are addressing various aspects of SCI, from neuroprotection and axonal regeneration to neuropathic pain relief and nervous system repair. These therapies are expected to drive substantial growth in the SCI market, which is projected to expand from $354 million in 2025 to $1.4 billion by 2034.

Why it matters

Despite the devastating impact of spinal cord injuries, the current treatment landscape remains limited, with only one approved disease-modifying therapy available exclusively in Japan. The emergence of these innovative pipeline candidates represents a critical shift in how the medical community approaches SCI, transitioning from symptomatic management to therapies that address the underlying pathophysiology of neuronal injury and degeneration.

The details

The SCI pipeline features a diverse array of therapeutic approaches, including growth factor-based neuroprotection (KP-100IT), autologous stem cell therapy for regeneration and immunomodulation (Neuro-Cells), monoclonal antibodies targeting axonal growth inhibitors (MT-3921, Elezanumab), lipid-based neuropathic pain relief (NFX88), and a first-in-class neurorepair peptide (NVG-291). These therapies are progressing through various stages of clinical development, with some already receiving regulatory designations like Orphan Drug and Fast Track status.

  • In 2019, Japan's MHLW granted KP-100IT orphan drug designation.
  • In 2024, Keio University initiated a collaborative research effort to identify biomarkers associated with spontaneous recovery following SCI.
  • In June 2025, Kringle Pharma announced that the U.S. FDA had also granted orphan drug designation to KP-100IT for the treatment of acute-phase spinal cord injury.
  • In September 2023, Neuroplast completed patient enrollment in its Phase II clinical study assessing Neuro-Cells in traumatic spinal cord injury.
  • In July 2021, the US FDA awarded Fast Track Designation to MT-3921, enabling accelerated regulatory interactions to advance its development for SCI.

The players

Kringle Pharma

A Japanese pharmaceutical company developing KP-100IT, an intrathecal therapy that uses hepatocyte growth factor (HGF) to treat acute spinal cord injury.

Neuroplast

A Dutch biotechnology company developing Neuro-Cells, an advanced autologous stem cell therapy for traumatic spinal cord injury.

Mitsubishi Tanabe Pharma America

The American subsidiary of the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation, developing MT-3921, a monoclonal antibody targeting RGMa for spinal cord injury.

AbbVie

A global biopharmaceutical company developing Elezanumab, a human IgG1 monoclonal antibody targeting repulsive guidance molecule A (RGMa) for spinal cord injury.

Neurofix

A pharmaceutical company developing NFX88, a novel lipid-based therapy designed to address neuropathic pain often experienced by individuals with spinal cord injuries.

Got photos? Submit your photos here. ›

What they’re saying

“KP-100IT is emerging as a promising therapy, with DelveInsight projecting market penetration reaching ~USD 27 million in 2034 across the 7MM.”

— Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight

“Neuroplast's Neuro-Cells is emerging as the second-largest growth opportunity in the SCI pipeline from DelveInsight's perspective, with projected market penetration reaching USD 270 million in 2034 across the 7MM, substantially exceeding KP-100IT's projections despite anticipated regulatory approval later in 2034.”

— Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight

“MT-3921 stands out as a critical-path asset in the SCI pipeline, with a projected market penetration of USD 367 million by 2034, positioning it as the second-largest single-asset opportunity in the 7MM SCI market.”

— Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight

“Elezanumab stands out as a major competitive threat to MT-3921, achieving the highest single-asset market projection in the emerging SCI pipeline, with revenues expected to reach USD 437 million in 2034.”

— Ramandeep, Senior Consultant, Forecasting and Analytics at DelveInsight

What’s next

Following the successful completion of Phase IIA, Neurofix Pharma is preparing to advance NFX88 into Phase IIB/III trials later this year. This critical study will span around 30 hospitals across multiple EU countries and represents the final stage before potential commercialization, contingent on positive outcomes.

The takeaway

The emerging spinal cord injury therapeutic landscape represents one of the pharmaceutical industry's most compelling transformation opportunities. With STEMIRAC as the sole FDA-approved option (Japan-exclusive), these emerging therapies addressing fundamentally distinct pathophysiological mechanisms position the SCI market for explosive growth from $354 million (2025) to $1.4 billion (2034), revolutionizing the treatment of this debilitating condition.